Rituxan 500 MG/50 ML vial 50ML
Ended Awarded Last action
- Contract number
- SPE2DR26FHKT4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,221
Award facts
- Contract value 100% obligated
- $15,221.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $15,221.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Rituxan 500 mg/50 ml vials. The delivery order, issued on December 15, 2025, with an ultimate completion date of January 7, 2026, carries no set-aside designation, indicating DMS Pharmaceutical Group competed successfully in unrestricted federal procurement. Performance will take place at the contractor's Park Ridge, Illinois facility.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy designed to supply pharmaceutical products to military healthcare facilities worldwide. The underlying IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's established performance on numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the Department of Defense military medical system across multiple therapeutic categories, including biologics, specialty pharmaceuticals, and branded and generic medications.
Quick answers
Who was awarded contract SPE2DR26FHKT4?
SPE2DR26FHKT4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FHKT4 worth?
The government has obligated $15,221 on SPE2DR26FHKT4.
Is contract SPE2DR26FHKT4 an order under another contract?
Yes. SPE2DR26FHKT4 is a delivery order under SPE2DR25D9222, an indefinite delivery contract.
Was contract SPE2DR26FHKT4 competed?
The extent of competition for SPE2DR26FHKT4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award